S&P 500   5,051.41 (-0.21%)
DOW   37,798.97 (+0.17%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
S&P 500   5,051.41 (-0.21%)
DOW   37,798.97 (+0.17%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
S&P 500   5,051.41 (-0.21%)
DOW   37,798.97 (+0.17%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
S&P 500   5,051.41 (-0.21%)
DOW   37,798.97 (+0.17%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
Free Trial
OTCMKTS:AXIM

AXIM Biotechnologies (AXIM) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free AXIM Stock Alerts
$0.02
0.00 (0.00%)
(As of 04/15/2024 ET)
Compare
Today's Range
$0.0115
▼
$0.0176
50-Day Range
$0.0103
▼
$0.0193
52-Week Range
$0.01
▼
$0.05
Volume
231,091 shs
Average Volume
442,339 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest
AXIM stock logo

About AXIM Biotechnologies Stock (OTCMKTS:AXIM)

AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and other diseases. The company is developing tests for dye eye diseases; SARS-CoV-2 neutralizing antibody tests; and fentanyl neutralizing antibody tests. It also developing a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.

AXIM Stock Price History

AXIM Stock News Headlines

April 4, 2024 | msn.com
Axim youth appeal for sports infrastructure
March 27, 2024 | globenewswire.com
VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024
April 16, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
March 7, 2024 | msn.com
We Want Peaceful Elections – Axim Youth
February 20, 2024 | finance.yahoo.com
AXIM® Biotechnologies’ Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation
February 20, 2024 | globenewswire.com
AXIM® Biotechnologies' Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation
February 7, 2024 | msn.com
Axim Fishermen Hail Govt
February 6, 2024 | msn.com
MASLOC Trial: Daniel Axim Denies Charges
April 16, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
December 21, 2023 | msn.com
AXIM and Auer partner for dry eye disease assay production
December 20, 2023 | finance.yahoo.com
AXIM® Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production
December 11, 2023 | msn.com
Tullow builds 14-unit dormitory block for Axim Girls SHS
December 2, 2023 | seekingalpha.com
LLBO Lifeline Biotechnologies, Inc.
December 2, 2023 | seekingalpha.com
CollPlant Biotechnologies Ltd. (CLGN) Q3 2023 Earnings Call Transcript
November 8, 2023 | msn.com
Court Orders Mental Test For Axim In MASLOC Trial
November 1, 2023 | msn.com
Axim Fishermen Plead For More Premix
September 12, 2023 | stockhouse.com
AXIM® Biotechnologies Develops First Non-Invasive, Rapid, Point-of-Care, Diagnostic Test for Parkinson's Disease
September 12, 2023 | finance.yahoo.com
AXIM® Biotechnologies Develops First Non-Invasive, Rapid, Point-of-Care, Diagnostic Test for Parkinson’s Disease
September 10, 2023 | finance.yahoo.com
AXIM - AXIM Biotechnologies, Inc.
August 1, 2023 | finance.yahoo.com
AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test
July 12, 2023 | finance.yahoo.com
Update: AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
July 12, 2023 | finance.yahoo.com
Update: AXIM Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
July 12, 2023 | finance.yahoo.com
AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
June 14, 2023 | markets.businessinsider.com
NV5's Newly Acquired Subsidiary Axim Pockets Contract From National Geospatial Intelligence Agency
May 24, 2023 | finance.yahoo.com
AXIM Biotechnologies Announces Over 40 Initial Clinic Commitments for Its Full Diagnostic Assay Platform Launch
May 23, 2023 | finance.yahoo.com
AXIM® Biotechnologies Appoints Kurt Phinney as Chief Operating Officer to Drive Scaling and Optimization of Manufacturing Unit
May 20, 2023 | businesswire.com
iXCells Biotechnologies Expands CRISPR-Cas9 Cell Products and Genome Engineering Services
See More Headlines
Receive AXIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AXIM Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/16/2024
Next Earnings (Estimated)
4/17/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:AXIM
CUSIP
N/A
CIK
1514946
Web
aximbiotech.com
Phone
(858) 923-4422
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
Elon Musk's Next Move Cover
Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. John W. Huemoeller II (Age 69)
    President, CEO & Director
    Comp: $420k
  • Mr. Robert T. Malasek (Age 56)
    CFO & Secretary
    Comp: $90k
  • Ms. Catalina Valencia J.D. (Age 75)
    Co-Founder & CEO of Sapphire Biotech, Inc.
    Comp: $187.5k
  • Mr. Kurt Phinney (Age 52)
    Chief Operating Officer
  • Dr. Sergei A. Svarovsky M.B.A.
    Ph.D., Chief Scientific Officer & Co-Founder of Sapphire Biotech, Inc.
  • Dr. Alim Seit-Nebi Ph.D.
    CTO & Co-Founder of Sapphire Biotech, Inc.
  • Mr. Jeffrey A. Busby
    Senior Vice President of Business Development
  • Dr. Joseph Tauber M.D. (Age 67)
    Chief Medical Officer & Chairman of the Medical Advisory Board

Key Competitors

View All Competitors

AXIM Stock Analysis - Frequently Asked Questions

How have AXIM shares performed in 2024?

AXIM Biotechnologies' stock was trading at $0.0190 at the beginning of the year. Since then, AXIM stock has decreased by 17.9% and is now trading at $0.0156.
View the best growth stocks for 2024 here.

When is AXIM Biotechnologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 17th 2024.
View our AXIM earnings forecast.

What other stocks do shareholders of AXIM Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AXIM Biotechnologies investors own include Cronos Group (CRON), Tilray (TLRY), KushCo (KSHB), Curaleaf (CURLF), Charlotte's Web (CWBHF), Fulcrum Therapeutics (FULC) and Alibaba Group (BABA).

How do I buy shares of AXIM Biotechnologies?

Shares of AXIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:AXIM) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
Can't believe it's happening again
Manward Press
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
Biden’s $374B Giveaway Into This Sector
DTI
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Options trading has suddenly become more reliable.
Eagle Publishing
Top 5 AI Stocks to Buy for 2024
Market Moving Trends